Dashboard
Manage Tickers

SCYX SCYNEXIS INC


$ 0.77 $ 0.00 (0 %)    

Tuesday, 21-Oct-2025 08:50:28 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
$ 0.78
$ 0.76 x 100
$ 0.80 x 100
-- - --
$ 0.66 - $ 1.60
341,699
na
32.28M
$ 1.68
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

trading-halt-halt-status-updated-at-82000-am-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 8:20:...
10/15/2025 12:20:04

Core News & Articles
SCYNEXIS To Receive $22M From GlaxoSmithKl...
10/15/2025 12:08:33

SCYNEXIS to receive a $22 million payment as part of the resolution related to the restart of the Phase 3 MARIO study on invasi...

trading-halt-halted-at-75500-am-et---trading-halt-halt-news-pending
Trading Halt: Halted at 7:55:00 a.m. ET - ...
10/15/2025 11:55:04

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
10/02/2025 12:09:25

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
09/30/2025 21:06:48

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
09/30/2025 17:06:34

scynexis-reports-results-from-phase-1-study-of-scy-247-second-gen-triterpenoid-antifungal-under-development-for-treatment-and-prevention-of-invasive-fungal-infections
SCYNEXIS Reports Results From Phase 1 Stud...
09/30/2025 12:07:48

No safety concerns or dose limiting toxicities observedSCY-247 was able to achieve target exposures at doses lower than our fir...

scynexis-to-present-at-12th-congress-on-trends-in-medical-mycology-sept-19-22
SCYNEXIS To Present At 12th Congress on Tr...
09/04/2025 12:38:56

scynexis-q2-eps-014-beats-019-estimate-sales-1364m-beat-154000k-estimate
SCYNEXIS Q2 EPS $(0.14) Beats $(0.19) Esti...
08/13/2025 20:34:53

SCYNEXIS (NASDAQ:SCYX) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.19) by 2...

scynexis-announces-nasdaq-noncompliance-letter
SCYNEXIS Announces Nasdaq Noncompliance Le...
06/26/2025 20:04:59

-SEC Filing

scynexis-resumes-patient-dosing-in-phase-3-mario-study-following-lifting-of-clinical-hold
SCYNEXIS Resumes Patient Dosing In Phase 3...
05/28/2025 12:35:22

scynexis-q1-eps-011-beats-017-estimate-sales-25700k-beat-20550k-estimate
SCYNEXIS Q1 EPS $(0.11) Beats $(0.17) Esti...
05/15/2025 20:50:34

SCYNEXIS (NASDAQ:SCYX) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.17) by 3...

scynexis-to-present-preclinical-data-on-second-generation-ivoral-fungerp-scy-247-at-the-european-society-of-clinical-microbiology-and-infectious-diseases
SCYNEXIS To Present Preclinical Data On Se...
04/08/2025 12:57:32

SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-trea...

scynexis-2024-gaap-eps-044-down-from-139-yoy-sales-375m-down-from-14014m-yoy
SCYNEXIS 2024 GAAP EPS $(0.44) Down From $...
03/12/2025 21:19:44

scynexis-initiates-dosing-in-phase-1-trialoof-scy-247-for-invasive-fungal-infections
SCYNEXIS Initiates Dosing In Phase 1 Trial...
12/18/2024 13:16:28

scynexis-q3-eps-006-beats-007-estimate
SCYNEXIS Q3 EPS $(0.06) Beats $(0.07) Esti...
11/06/2024 22:27:11

SCYNEXIS (NASDAQ:SCYX) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.07) by 1...

scynexis-to-present-preclinical-data-on-second-generation-fungerp-scy-247-at-idweek-2024
SCYNEXIS To Present Preclinical Data On Se...
10/03/2024 12:21:56

SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-trea...

scynexis-q1-2024-gaap-eps-001-beats-020-estimate-sales-1400m-beat-303000k-estimate
SCYNEXIS Q1 2024 GAAP EPS $0.01 Beats $(0....
05/08/2024 22:37:31

SCYNEXIS (NASDAQ:SCYX) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.20) by 1...

scynexis-presented-preclinical-data-on-second-generation-fungerp-scy-247-at-the-congress-of-the-european-society-of-clinical-microbiology-and-infectious-diseases
SCYNEXIS Presented Preclinical Data On Sec...
04/30/2024 20:39:47

In vivo data demonstrated efficacy of SCY-247 in mouse model of invasive candidiasis caused by Candida glabrata SCY-247 showed ...

cantor-fitzgerald-reiterates-overweight-on-scynexis
Cantor Fitzgerald Reiterates Overweight on...
04/01/2024 12:31:45

Cantor Fitzgerald analyst Louise Chen reiterates SCYNEXIS (NASDAQ:SCYX) with a Overweight.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION